Baxter International (BAX) Stock Forecast & Price Target

$31.32 -2.33 (-6.92%)

Closing price 03:59 PM Eastern

Extended Trading

$31.47 +0.15 (+0.48%)

As of 07:55 PM Eastern

Baxter International - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 10 Analyst Ratings

Sell
1

Hold
4

Buy
5

Based on 10 Wall Street analysts who have issued ratings for Baxter International in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 1 has given a sell rating, 4 have given a hold rating, and 5 have given a buy rating for BAX.

Consensus Price Target

$38.56
23.10% Upside

According to the 10 analysts' twelve-month price targets for Baxter International, the average price target is $38.56. The highest price target for BAX is $45.00, while the lowest price target for BAX is $30.00. The average price target represents a forecasted upside of 23.10% from the current price of $31.32.

Get the Latest News and Ratings for BAX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Baxter International and its competitors.

BAX Analyst Ratings Over Time

Type	Current Forecast 4/3/24 to 4/3/25	1 Month Ago 3/4/24 to 3/4/25	3 Months Ago 1/4/24 to 1/3/25	1 Year Ago 4/4/23 to 4/3/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$38.56	$39.00	$40.45	$46.45
Forecasted Upside	23.10% Upside	12.09% Upside	37.13% Upside	7.31% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Remove Ads

BAX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BAX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Baxter International Stock vs. The Competition

Type	Baxter International	Medical Companies	S&P 500
Consensus Rating Score	2.40	2.81	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	23.10% Upside	19,391.32% Upside	25.01% Upside
News Sentiment Rating	Neutral News See Recent BAX News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/10/2025	Barclays 3 of 5 stars	M. Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$39.00 ➝ $41.00	+12.00%
2/26/2025	The Goldman Sachs Group 3 of 5 stars	David Roman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy	$42.00	+16.66%
2/24/2025	Argus 2 of 5 stars	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
2/21/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$38.00 ➝ $36.00	+7.50%
12/11/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$37.00 ➝ $35.00	+12.90%
11/11/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$46.00 ➝ $38.00	+11.73%
8/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$44.00 ➝ $40.00	+6.84%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Equal Weight ➝ Underweight	$39.00 ➝ $30.00	-15.06%
7/2/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$46.00 ➝ $45.00	+36.12%
5/10/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$40.00	+11.27%
Get the Latest News and Ratings for BAX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Baxter International and its competitors with MarketBeat's FREE daily newsletter.
3/5/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$42.00 ➝ $45.00	+2.93%
2/6/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$40.00 ➝ $36.00	-8.28%
10/24/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$35.00 ➝ $50.00	+52.72%
7/31/2023	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$53.00 ➝ $51.00	+8.49%
5/30/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Assumes

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:35 PM ET.

Should I Buy Baxter International Stock? BAX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 30, 2025. Please send any questions or comments about these Baxter International pros and cons to contact@marketbeat.com.

Baxter International
Bull Case

Here are some ways that investors could benefit from investing in Baxter International Inc.:

Baxter International Inc. has received multiple upgrades from analysts, including a recent upgrade to a "buy" rating by Argus, indicating positive sentiment and potential for stock appreciation.
The company reported earnings per share (EPS) of $0.58, exceeding the consensus estimate of $0.52, which reflects strong financial performance and operational efficiency.
As of the latest trading session, Baxter International Inc. shares are priced at $34.64, which is within a reasonable range compared to its 52-week high of $43.99, suggesting potential for growth.
Institutional ownership is high, with 90.19% of the company's stock held by hedge funds and other large investors, indicating confidence in the company's future prospects.
Baxter International Inc. has a diversified portfolio across healthcare segments, which can provide stability and growth opportunities in various market conditions.

Baxter International
Bear Case

Investors should be bearish about investing in Baxter International Inc. for these reasons:

The company has a negative net margin of 5.05%, which suggests that it is currently not profitable, raising concerns about its ability to generate sustainable earnings.
Baxter International Inc. has a high debt-to-equity ratio of 1.31, indicating that the company is heavily reliant on debt financing, which can be risky in volatile market conditions.
Despite recent upgrades, the consensus rating remains a "Hold," which may imply that analysts are cautious about the stock's short-term performance.
The stock has experienced fluctuations, with a recent drop of 1.7%, which may indicate volatility and uncertainty in the market.
Citigroup recently lowered its target price for Baxter International Inc. from $37.00 to $35.00, suggesting a more cautious outlook on the stock's potential for growth.

BAX Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Baxter International is $38.56, with a high forecast of $45.00 and a low forecast of $30.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last twelve months. There is currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BAX, but not buy additional shares or sell existing shares.
: According to analysts, Baxter International's stock has a predicted upside of 23.10% based on their 12-month stock forecasts.
: Over the previous 90 days, Baxter International's stock had 1 upgrade by analysts.
: Baxter International has been rated by research analysts at Argus, Barclays, JPMorgan Chase & Co., and The Goldman Sachs Group in the past 90 days.
: Analysts like Baxter International less than other "medical" companies. The consensus rating for Baxter International is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BAX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:BAX) was last updated on 4/3/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Baxter International (BAX) Stock Forecast & Price Target